Moderna Inc MRNA.O will supply 12 million doses of its COVID-19 shot adapted to target the Omicron variant of the coronavirus to Canada, the company said on Monday.
The Canadian government had entered into a supply deal with the company last year for supply of its COVID vaccine for 2022 and 2023, with the contract allowing access to new vaccine adaptations.
Moderna and Canada have agreed to convert six million doses of the company’s COVID-19 vaccine, which targets the original virus, to an Omicron-containing bivalent vaccine.
Get weekly health news
Canada will also purchase an additional 4.5 million doses of the Omicron-containing candidate, and is moving forward the scheduled delivery of 1.5 million doses of the bivalent vaccine candidate from 2023 to 2022.
While existing COVID-19 vaccines continue to provide protection against hospitalization and death, vaccine effectiveness has taken a hit as the virus has evolved.
Moderna in June said trial data showed that when given as a fourth dose, the variant-adapted shot raised virus-neutralizing antibodies by eight-fold against Omicron.
- PHAC finds no evidence of mystery brain disease in New Brunswick, says patients still need answers
- Beer recall hits 2 more Canadian products, bringing total to 31
- Alberta expanding use of AI tech that speeds up MRIs after successful pilot
- Stopping GLP-1 drugs could increase heart attack risk for some, study says
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
Comments
Want to discuss? Please read our Commenting Policy first.